Meropenem Completed Phase 4 Trials for Cholangitis, Secondary Biliary / Compliance, Treatment / anti-drug antibody development Treatment

Indications	Status	Purpose	Phase
DBCOND0128855 (Cholangitis, Secondary Biliary) DBCOND0121821 (Compliance, Treatment) DBCOND0103177 (anti-drug antibody development)	Completed	Treatment	4

clinicaltrials.gov Identifier	Title	Drugs
NCT04370145	Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy	Cefoperazone (DB01329) Meropenem (DB00760) Sulbactam (DB09324) Teicoplanin (DB06149) Tinidazole (DB00911)